CRMI (08158) intends to form a strategic partnership with China Star and acquire 55% of Kangmei Zan's shares.
China Regenerative Medicine (08158) announced that on January 2, 2026, China Regenerative (Hong Kong) Investment Limited (a wholly-owned subsidiary of the Company) entered into a purchase agreement with China Star Entertainment (BVI) Limited (China Star) (a wholly-owned subsidiary of China Star Group Limited (a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 0326)). China Regenerative (Hong Kong) agreed to acquire 55% of the equity interest in Conricorn BioTech Development Limited (formerly known as Hong Kong Dypu Culture Media Limited) (a wholly-owned subsidiary of China Star) for a consideration of HK$5500.
CRMI (08158) announces that on January 2, 2026, Central Recycling (Hong Kong) Investment Limited (a wholly-owned subsidiary of the Company) and China Star Entertainment (BVI) Limited (China Star) (a wholly-owned subsidiary of China Star Entertainment Limited (a company listed on the Main Board of the Hong Kong Stock Exchange with stock code: 0326)) have entered into a sale and purchase agreement. Central Recycling (Hong Kong) has agreed to acquire 55% equity interests in Comus International Biotech Development Limited (formerly known as Disney Culture Media Limited) (a wholly-owned subsidiary of China Star) for a consideration of HK$5,500. After the completion of the acquisition, Central Recycling (Hong Kong) and China Star will hold 55% and 45% equity interests in Comus International, respectively. The transaction under the sale and purchase agreement will be completed simultaneously.
To regulate the rights and obligations of Central Recycling (Hong Kong) and China Star as shareholders of Comus International, Central Recycling (Hong Kong), China Star, and Comus International have entered into a shareholders' agreement upon completion of the sale and purchase agreement.
Furthermore, Comus International will serve as an investment holding company, investing in Macau, China, and collaborating with other strategic investors to operate clinics in Macau.
This strategic collaboration will further leverage the respective professional capabilities and resource advantages of all parties involved. On the one hand, the Group can enhance its business competitiveness in Macau by leveraging China Star's resources and business relationships in the region; on the other hand, Comus International can benefit from the Group's industry resources and extensive experience in aesthetic medical and beauty services as well as medical services to achieve synergies.
The strategic collaboration marks an important milestone for the Group's expansion into the new market of Macau. Through collaboration, all parties will achieve synergistic growth in their respective businesses and bring new market opportunities and commercial value to their companies.
Related Articles

OIWAHPAWN (01319) grant a loan of HKD 55 million

China Rare Earth Resources And Technology (00769) appoints Zheng Zheng as the external auditor.

FW HOLDINGS (00572) is selling 278 million shares of Little Fish before the merger and 5.58 million shares after the merger.
OIWAHPAWN (01319) grant a loan of HKD 55 million

China Rare Earth Resources And Technology (00769) appoints Zheng Zheng as the external auditor.

FW HOLDINGS (00572) is selling 278 million shares of Little Fish before the merger and 5.58 million shares after the merger.






